Labcorp (LH) announced the clinical availability of Labcorp Plasma Complete, a circulating tumor DNA-based comprehensive genomic profiling solution for patients with advanced solid tumors. The liquid biopsy test enables oncologists to perform comprehensive genomic profiling to inform personalized treatment decisions – all from a simple blood draw. Labcorp Plasma Complete detects genomic alterations in ctDNA across 521 genes. The assay covers established and emerging biomarkers associated with FDA-approved therapies, guideline-driven treatments and clinical trial eligibility, providing oncologists with key insights to support personalized patient care.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp price target raised to $260 from $240 at Piper Sandler
- Labcorp’s Earnings Call Highlights Growth and Optimism
- Labcorp price target raised to $248 from $231 at Deutsche Bank
- Robust Financial Performance and Positive Outlook Support Buy Rating for Labcorp Holdings
- Labcorp price target raised to $293 from $291 at Baird
Questions or Comments about the article? Write to editor@tipranks.com